Status:
COMPLETED
A Study of R547 in Patients With Advanced Solid Tumors.
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This single arm study will determine the maximum tolerated dose, and recommended dose for further development, of R547, in patients with advanced solid tumors. Groups of patients will receive ascendin...
Eligibility Criteria
Inclusion
- adult patients, \>=18 years of age;
- locally advanced or metastatic solid tumors;
- measurable or evaluable disease.
Exclusion
- prior chemotherapy, radiotherapy or immunotherapy within 3 weeks of start of study;
- prior history of CNS metastases with disease progression;
- patients taking strong inhibitors and/or inducers of CYP3A4.
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT00400296
Start Date
May 1 2005
End Date
November 1 2008
Last Update
November 2 2016
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Aurora, Colorado, United States, 80045
2
New Brunswick, New Jersey, United States, 08901
3
Charlotte, North Carolina, United States, 28203
4
Houston, Texas, United States, 77030